ACC 2019 | The New ACC/AHA Guidelines on Primary Prevention Focus on Life Style, Diet and Socioeconomic Factors.

These guidelines basically remind us that we should focus on life style changes to best prevent heart disease, heart failure and atrial fibrillation. These changes, of course, should be permanent.

ACC 2019 | Las nuevas guías de prevención primaria ACC/AHA con foco en estilo de vida, dieta y factores socioeconómicos.It is estimated that life style changes translate into 80% risk reduction of heart disease.

 

These recommendations are based on 9 topics: risk estimation, diet, physical activity, obesity, diabetes, cholesterol, hypertension, giving up smoking and the use of aspirin.

 

Social factors have been one of the most difficult fronts and the one with most impact. Physicians seldom show concern about whether patients can afford the drugs we prescribe, or whether they will be able to follow a healthy diet.


Read also: ACC 2019 | SAFARI: Unexpectedly, Radial Approach Offers No Benefits In STEMI.


Moreover, we should routinely try to detect psychosocial stressors and support our patients with savvy advice.

 

For adults between 40 and 75, we recommend screening for traditional risk factors and estimating cardiovascular risk at 10 years (recommendation class I).

 

For patients between 20 and 39, it is reasonable to assess risk factors every 4 to 6 years (recommendation class IIa).


Read also: ACC 2019 | POET: Oral Antibiotics with Good Long-Term Results for Endocarditis.


Patients presenting intermediate or border risk could be better stratified with other markers such as family history, metabolic syndrome, chronic kidney disease, or C-reactive protein.

 

Guidelines also suggest consuming more vegetables, fruits, legumes, whole grains and fish, as well as warning against the consumption of salt, fired foods, processed meats and sugary drinks.

 

They recommend 150 minutes of moderate activity (walking, swimming, cycling) or 75 minutes of a more vigorous activity, and if neither were possible, at least 10 minutes can make a significant difference.


Read also: ACC 2019 | Having an Infarction at Very Young Age or 10 Years Later Does Not Change Long-Term Mortality.


As regards aspirin, it is not recommended as primary prevention in >70-year individuals, or with increased bleeding risk (recommendation class III). For individuals between 40 and 70, aspirin can be considered if there is high cardiovascular risk or low bleeding risk (recommendation class IIb). For most patients, aspirin is not indicated as primary prevention.

 

Original title: 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease.

Reference: Arnett DK et al. Circulation 2019; Epub ahead of print.

 


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Ticagrelor vs Clopidogrel in ACS Patients Receiving DOAC After PCI: More Bleeding Without Ischemic Benefit?

In patients with acute coronary syndrome (ACS) who require direct oral anticoagulation (DOAC) and undergo percutaneous coronary intervention (PCI), current guidelines recommend a dual...

EuroPCR 2026 | P2Y12 Inhibitor Monotherapy After Complex PCI in ACS: Results From the NEO-MINDSET COMPLEX Subanalysis

This is a summary of the NEO-MINDSET COMPLEX subanalysis, presented by Dr. Guy Prado at EuroPCR 2026, which evaluated P2Y12 inhibitor monotherapy versus dual...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

SPYRAL Program: 3-Year Outcomes in Patients Treated with Renal Denervation

Hypertension is the leading modifiable risk factor for cardiovascular disease and remains a major global health challenge, affecting more than one billion adults worldwide.  Despite...

Coronary Obstruction During TAVI: A New Volumetric Index to Consider

Coronary obstruction during TAVI is an uncommon but potentially catastrophic complication, particularly in valve-in-valve procedures, in anatomies with small sinuses of Valsalva, low coronary...

EARLY TAVR: Impact of Age on Outcomes of Early TAVR in Asymptomatic Patients

Asymptomatic severe aortic stenosis represents an increasingly common clinical challenge. Although current guidelines recommend intervention once symptoms develop or left ventricular dysfunction occurs, concerns...